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Abstract
Background: Intracranial and intraspinal tumours are the most numerous solid tumours in children. Some recently
defined subtypes are relatively frequent in childhood. Many cancer registries routinely ascertain CNS tumours of all
behaviours, while others only cover malignant neoplasms. Some behaviour codes have changed between revisions
of the International Classification of Diseases for Oncology, including pilocytic astrocytoma, downgraded to
uncertain behaviour in ICD-O-3.
Methods: We used data from the population-based National Registry of Childhood Tumours, which routinely
included non-malignant CNS tumours, to document the occurrence of CNS tumours among children aged < 15
years in Great Britain during 2001–2010 and to document the descriptive epidemiology of childhood CNS tumours
over the 40-year period 1971–2010, during which several new entities were accommodated in successive editions
of the WHO Classification and revisions of ICD-O. Eligible cases were all those with a diagnosis included in Groups
III (CNS tumours) and Xa (CNS germ-cell tumours) of the International Classification of Childhood Cancer, Third
Edition. The population at risk was derived from annual mid-year estimates by sex and single year of age compiled
by the Office for National Statistics and its predecessors. Incidence rates were calculated for age groups 0, 1–4, 5–9
and 10–14 years, and age-standardised rates were calculated using the weights of the world standard population.
Results: Age-standardised incidence in 2001–10 was 40.1 per million. Astrocytomas accounted for 41%, embryonal
tumours for 17%, other gliomas for 10%, ependymomas for 7%, rarer subtypes for 20% and unspecified tumours for
5%. Incidence of tumours classified as malignant and non-malignant by ICD-O-3 increased by 30 and 137%
respectively between 1971-75 and 2006–10.
Conclusions: Total incidence was similar to that in other large western countries. Deficits of some, predominantly
low-grade, tumours or differences in their age distribution compared with the United States and Nordic countries
are compatible with delayed diagnosis. Complete registration regardless of tumour behaviour is essential for
assessing burden of disease and changes over time. This is particularly important for pilocytic astrocytoma, because
of its recent downgrading to non-malignant and time trends in the proportion of astrocytomas with specified
subtype.
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Background
Intracranial and intraspinal tumours are the most frequent
solid tumours in children. Age-standardised incidence at age
0–14 years in industrialised countries during the 1980s–90s
was typically in the range 30–40 per million [1, 2]. Successive
standard classifications of childhood cancer, while generally
restricted to neoplasms of malignant behaviour, have also ad-
mitted non-malignant tumours of the brain, spinal cord,
meninges and intracranial endocrine glands because benign
tumours of these sites are potentially lethal and it can be pe-
culiarly difficult to determine the behaviour of some tu-
mours, especially in the absence of histology [3–6]. Many
population-based general cancer registries, and all specialist
children’s cancer registries, have for a long time routinely
ascertained these non-malignant tumours for the same rea-
sons. Other registries traditionally confined their coverage to
malignant neoplasms, however, including most of those in
the United States until they were mandated to include
non-malignant CNS tumours from 2004 onwards. In the in-
terests of comparability, successive volumes of Cancer Inci-
dence in Five Continents have always been restricted to
malignant neoplasms [7, 8]. By contrast, the two volumes of
International Incidence of Childhood Cancer [1, 9] and the
Automated Childhood Cancer Information System [2] in-
cluded intracranial and intraspinal tumours regardless of be-
haviour, but provided information on the proportion
specified as malignant.
In the past three decades, new types of intracranial
and intraspinal neoplasms have been defined, including
several that are relatively frequent in childhood [10–13]
(Tables 1 and 2). Some are non-malignant tumours that
would previously have been included within a less spe-
cific entity that was regarded as malignant. Some entities
changed behaviour code between revisions of the Inter-
national Classification of Diseases for Oncology (ICD-O)
[14–16] (Table 1). Mostly these affected only small num-
bers of cases, but pilocytic or juvenile astrocytoma, the
most frequent of all childhood central nervous system
(CNS) tumours, was downgraded from malignant to un-
certain behaviour in ICD-O-3, published in 2000 [16].
There are few detailed accounts of the occurrence of
childhood CNS tumours based on large series from
population-based cancer registries using data coded to
ICD-O-3 [17, 18].
This study has two principal aims. The first is to give a
detailed and up to date account of the occurrence of
Table 1 Changes and additions to morphology codes for intracranial and intraspinal tumours between ICD-O-1 (1976) [14], ICD-O-2
(1990) [15] and ICD-O-3 (2000) [16]. Changes to behaviour code are in bold italics. ICCC-3: category in International Classification of
Childhood Cancer, Third Edition [6]
Entity ICD-O-1 ICD-O-2 ICD-O-3 ICCC-3
Papillary ependymoma 9393/1 9393/1 9393/3 IIIa.1
Pilocytic astrocytoma 9421/3 9421/3 9421/1 IIIb
Spongioblastoma, NOS 9422/3 9422/3 9421/1 IIIb
Pleomorphic xanthoastrocytoma – 9424/3 9424/3 IIIb
Gliofibroma – – 9442/1 IIIb
Large cell medulloblastoma – – 9474/3 IIIc.1
Primitive neuroectodermal tumour, NOS (now Embryonal CNS tumour, NOS) – 9473/3 9473/3 IIIc.2
Atypical teratoid/rhabdoid tumour – 8963/3 9508/3 IIIc.4
Chordoid glioma – – 9444/1 IIId.3
Prolactinoma – 8271/0 8271/0 IIIe.1
Pituitary adenoma, NOS 8140/0 8140/0 8272/0 IIIe.1
Pituitary carcinoma, NOS 8010/3 8010/3 8272/3 IIIe.1
Adamantinomatous craniopharyngioma – – 9351/1 IIIe.2
Papillary craniopharyngioma – – 9352/1 IIIe.2
Granular cell tumour of the sellar region 9580/0 9580/0 9582/0 IIIe.2
Desmoplastic infantile astrocytoma – – 9412/1 IIIe.4
Dysembryoplastic neuroepithelial tumour – – 9413/0 IIIe.4
Gangliocytoma – 9490/0 9492/0 IIIe.4
Dysplastic gangliocytoma of cerebellum – – 9493/0 IIIe.4
Anaplastic ganglioglioma – – 9505/3 IIIe.4
Clear cell meningioma 9538/1 IIIe.5
Papillary meningioma 9538/1 9538/1 9538/3 IIIe.5
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childhood intracranial and intraspinal tumours based on
data from a large, population-based, specialist children’s
tumour registry, including information on subtypes that
were not assigned specific morphology codes until
ICD-O-3. The second is to use data from the same regis-
try to document the descriptive epidemiology of child-
hood CNS tumours over a longer period during which
new entities were accommodated in successive editions
of the WHO Classification [10–12] and revisions of
ICD-O [15, 16, 19].
Methods
The population-based National Registry of Childhood Tu-
mours (NRCT) covered the population under 15 years of age
throughout Great Britain (England, Scotland and Wales)
during 1962–2010. Sources of notification varied slightly
over the years but always included the network of regional
and national cancer registries covering the population of all
ages in the whole of Great Britain, together with death certif-
icates for children with a neoplasm as underlying cause of
death. Cases were also ascertained from specialist children’s
tumour registries in certain regions of England. Since 1977
increasing numbers were notified directly from paediatric
oncology principal treatment centres [20]. The NRCTalways
included all malignant neoplasms and all non-malignant
intracranial and intraspinal tumours. Diagnoses were coded
according to ICD-O [14–16], with earlier data recoded retro-
spectively on adoption of each new revision. Further details
of the NRCTare published elsewhere [21]. Diagnoses for this
study were coded to ICD-O-3 [16] and grouped by the Inter-
national Classification of Childhood Cancer, Third Edition
(ICCC-3) [6]. Additional codes included in the first revision
of ICD-O-3 [19] were provisionally allocated to ICCC-3 cat-
egories (Table 2). Definitions for four existing codes were ex-
panded in line with the 2007 WHO Classification: 8290/0
includes spindle-cell oncocytoma, 9471/3 includes medullo-
blastoma with extensive nodularity, 9474/3 includes anaplas-
tic medulloblastoma, and 9506/1 includes extraventricular
neurocytoma and cerebellar liponeurocytoma [12, 19]. Add-
itional entities in the 2016 WHO Classification, many of
them genetically defined, could not be identified in the regis-
try data, but we have adopted the preferred terminology
‘embryonal CNS tumour NOS’ to replace ‘primitive neuroec-
todermal tumour (PNET)’ [13].
For this study we included all children who were
under the age of 15 years and resident in Great Britain
when diagnosed with a tumour included in ICCC-3
Group III ‘Central nervous system and miscellaneous
intracranial and intraspinal neoplasms’ or Subgroup Xa
‘Intracranial and intraspinal germ-cell tumours’ during
1971–2010. The main analyses are restricted to cases of
a first or only tumour in these ICCC-3 categories, but
brief details are also given of the small number of tu-
mours diagnosed in children with a previous cancer
diagnosis where it was clear from diagnostic and other
reports that these were distinct primary tumours. The
detailed description of incidence is based on children di-
agnosed during 2001–10. Data from the full 40-year
study period were used to describe changes in recorded
incidence and relative frequency over time and to show
the effects of restricting coverage to cases defined as ma-
lignant by successive revisions of ICD-O.
The population at risk was derived from annual
mid-year estimates by sex and single year of age com-
piled by the Office for National Statistics and its prede-
cessors. The average population at risk was 10.5 million
children during 2001–10 and 11.1 million children dur-
ing 1971–2010.
Registration rates were calculated per million child-years
at risk for age groups 0, 1–4, 5–9 and 10–14 years [1].
Age-standardised rates (ASR) were calculated by the direct
method, using the world standard population which assigns
weights 2.4, 9.6, 10 and 9 respectively to these age groups
[1]. Cumulative risk to 15th birthday was defined as the re-
ciprocal of the cumulative rate which was calculated as r0 +
4r1 + 5r2 + 5r3, where r0, r1, r2 and r3 are the age-specific
rates for ages 0, 1–4, 5–9 and 10–14 respectively [1].
Results
Incidence 2001–2010
Table 3 shows numbers of registrations for children di-
agnosed during 2001–10, percentage recorded as micro-
scopically verified (MV), annual rates per million
children by age group, and ASRs by sex and for both
sexes combined. Data are shown for ICCC-3 subgroups
Table 2 Additional ICD-O morphology codes proposed in the 2007 WHO Classification of Tumours of the Central Nervous System
and included in ICD-O-3.1 [19], with provisional allocation to categories in ICCC-3
Code Entity ICCC-3
9390/1 Atypical choroid plexus papilloma IIIa.2
9395/3 Papillary tumour of the pineal region IIId.3
9425/3 Pilomyxoid astrocytoma IIIb
9431/1 Angiocentric glioma IIId.3
9432/1 Pituicytoma IIId.3
9509/1 Papillary glioneural tumour/rosette-forming glioneuronal tumour of the fourth ventricle IIIe.4
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and divisions and the principal subtypes within them. A
total of 4166 tumours were registered, 2275 in boys and
1891 in girls. Numbers by age group were: age 0, 287;
age 1–4, 1213; age 5–9, 1320; age 10–14, 1346. Overall,
79% of cases were recorded as MV. The % MV exceeded
90% for many diagnostic subgroups and was over 80%
for the great majority but was only 8% for unspecified
optic nerve glioma/astrocytoma, 18% for unspecified gli-
oma of other sites and 20% for unspecified tumours.
The total ASR was 40.1 per million.
Ependymomas accounted for 7% of registrations. This sub-
group included ependymoblastoma, although it is usually
regarded as a type of embryonal tumour, because it shares a
morphology code with the more frequently occurring ana-
plastic ependymoma. Anaplastic ependymomas and ependy-
moblastoma accounted for 37% of ependymomas,
myxopapillary ependymoma for 10% and other specified
subtypes for 2%; 51% were of unspecified subtype. Ependy-
moma was generally most frequent at age 1–4 years, but
68% of myxopapillary ependymomas were diagnosed at age
10–14. Choroid plexus tumours accounted for 3% of regis-
trations. Of these, 56% were benign or unspecified papillo-
mas, 12% were atypical choroid plexus papillomas and 32%
were carcinomas. All types of choroid plexus tumour were
most often seen in the first year of life.
Astrocytomas were the largest diagnostic subgroup,
41% of all registrations. Fifty percent of all astrocytomas
were pilocytic. Subependymal giant cell astrocytoma
(SEGA), fibrillary astrocytoma and pilomyxoid astrocy-
toma each accounted for around 2%, pleomorphic
xanthoastrocytoma for 1% and other rare low-grade
(WHO Grade I and II) subtypes for 0.3%; 5% of astrocy-
tomas were anaplastic, 9% were glioblastoma and 28%
were of unspecified subtype. Among the 471 unspecified
astrocytomas, 249 (53%) were optic nerve gliomas. If all
optic nerve gliomas are assumed to have been
low-grade, 73% of all astrocytomas were low-grade, 14%
were high-grade (WHO Grade III-IV) and 13% were of
unspecified grade. Low-grade astrocytomas predomi-
nated in all age groups. The highest incidence of pilocy-
tic astrocytoma and unspecified optic nerve astrocytoma
was at age 1–4 years. Pleomorphic xanthoastrocytoma
was exceedingly rare before age 10 years, whereas by far
the highest incidence of pilomyxoid astrocytoma was in
the first year of life. For both subtypes of high-grade as-
trocytoma, anaplastic astrocytoma and glioblastoma,
there was an early peak of incidence in the first year of
life, a nadir at age 1–4 and somewhat higher incidence
at age 5 years and over.
Other gliomas accounted for 10% of registrations. The
great majority, 80%, were of unspecified subtype. Nearly
all the remainder were oligodendrogliomas (9%), mixed
gliomas (5%) or gliomatosis cerebri (3%). Incidence was
highest at age 5–9 years.
Embryonal tumours accounted for 17% of registra-
tions. Within this subgroup, 73% were medulloblastoma,
15% were embryonal CNS tumour NOS and 11% were
atypical teratoid/rhabdoid tumours (ATRT). Incidence of
medulloblastoma was highest at age 1–9 years, whereas
both embryonal CNS tumour NOS and ATRT were
most frequent in the first year of life. Three quarters of
medulloblastoma were of classical or unspecified sub-
type, 16% were desmoplastic/nodular or with extensive
nodularity, and 7% were large-cell/anaplastic. Incidence
of the desmoplastic/nodular subtype was highest at 1–4
years of age whereas the age distribution of the
large-cell/anaplastic subtypes was similar to that of clas-
sical/unspecified medulloblastoma, with highest inci-
dence at age 5–9 years.
The subgroup of other specified tumours, excluding
germ-cell tumours, accounted for 14% of registrations.
Mixed neuronal-glial tumours represented 39% of the
subgroup; within this category, 43% were gangliogliomas,
41% were dysembryoplastic neuroepithelial tumours
(DNET), and 9% were desmoplastic infantile astrocy-
toma (DIA). Tumours of the sellar region (craniopharyn-
giomas) represented 33% of the subgroup, pituitary
adenomas 12%, pineal parenchymal tumours 8% and
meningiomas 9%. Of the craniopharyngiomas, 41% were
adamantinomatous, one (< 1%) was papillary, and 58%
were of unspecified subtype. Among pituitary adenomas,
33% were prolactinomas, 9% were basophil adenomas
and 58% were unspecified.
Germ-cell tumours accounted for 4% of registrations.
They were mostly germinomas (70%) or teratomas
(25%). Germinomas occurred predominantly in the 10–
14 age group whereas teratomas were most frequent in
infancy.
Finally, 5% of registrations were for tumours of un-
specified type, mostly without microscopic verification.
The great majority (4007, 96%) of tumours in this
series were intracranial, but there were also 159 intrasp-
inal tumours, accounting for 3.8% and with an ASR of
1.6 per million. They comprised intramedullary and
extramedullary intradural tumours, together with extra-
dural ependymomas since the latter are included in
ICCC-3 Subgroup IIIa and occur at midline sites below
the head. The most frequent types of intraspinal tumour
were astrocytoma (47%) and ependymoma (26%).
Incidence 1971–2010
There were 14,281 registrations during the entire
40-year study period. Table 4 presents numbers of cases
and ASRs in successive 5-year periods, classified by
ICCC-3 and behaviour as defined by ICD-O-3. Within
subgroup IIIb, astrocytomas, pilocytic astrocytoma is
shown separately and registrations are also subdivided
by site (optic nerve and other) and ICD-O-3 behaviour.
Stiller et al. BMC Cancer          (2019) 19:139 Page 4 of 15
Table 3 Intracranial and intraspinal tumours among children aged 0–14 years resident in Great Britain, 2001–2010. Numbers of
registrations (N), % microscopically verified (MV), rates per million children by age group, age standardised rates (world standard
population) (ASR) by sex
ASR
ICCC-3 N %MV 0 1–4 5–9 10–14 M F Total
IIIa.1 Ependymoma 291 96.9 2.6 4.4 2.4 1.9 3.1 2.7 2.9
Unspecified 149 96.0 1.4 2.2 1.4 0.9 1.6 1.4 1.5
Anaplastic/ependymoblastoma 109 100 1.1 2.1 0.8 0.4 1.2 1.0 1.1
Papillary 3 66.7 – < 0.05 – 0.1 < 0.05 < 0.05 < 0.05
Myxopapillary 28 100 – 0.1 0.2 0.5 0.3 0.2 0.2
Subependymoma 2 0 – – < 0.05 < 0.05 – < 0.05 < 0.05
IIIa.2 Choroid plexus tumours 111 99.1 6.4 1.5 0.4 0.3 1.3 1.1 1.2
Papilloma 62 100 3.4 0.8 0.2 0.2 0.8 0.5 0.7
Atypical papilloma 13 100 1.0 0.1 0.1 – 0.1 0.2 0.1
Carcinoma 36 97.2 2.0 0.6 0.1 0.1 0.4 0.4 0.4
IIIb Astrocytoma 1707 81.7 11.1 19.4 16.5 14.7 16.4 16.5 16.5
Unspecified (optic nerve) 249 7.6 1.7 4.5 2.3 1.0 2.3 2.8 2.5
Unspecified (other sites) 222 82.9 1.3 2.5 2.3 1.9 2.3 2.0 2.1
Pilocytic 860 97.0 2.6 9.7 8.5 7.9 8.0 8.4 8.2
Subependymal giant cell 42 78.6 0.4 0.2 0.4 0.5 0.5 0.3 0.4
Gliofibroma 1 100 – – – < 0.05 – < 0.05 < 0.05
Protoplasmic 1 100 – < 0.05 – – – < 0.05 < 0.05
Gemistocytic 3 100 – – – 0.1 < 0.05 – < 0.05
Fibrillary 29 96.6 – 0.4 0.1 0.3 0.3 0.2 0.3
Pleomorphic xanthoastrocytoma 22 100 – 0.1 0.1 0.4 0.2 0.2 0.2
Pilomyxoid 38 97.4 1.6 0.5 0.1 0.2 0.4 0.4 0.4
Anaplastic 93 97.8 1.0 0.6 1.0 0.9 0.9 0.8 0.9
Glioblastoma 147 97.3 2.6 0.8 1.7 1.3 1.5 1.3 1.4
IIIc.1 Medulloblastoma 522 98.5 3.3 5.9 6.1 3.6 6.5 3.5 5.1
Unspecified 394 98.0 2.0 3.9 5.0 2.8 5.0 2.5 3.8
Desmoplastic/nodular/extensive nodularity 84 100 1.1 1.5 0.5 0.5 1.0 0.7 0.9
Medullomyoblastoma 6 100 – 0.1 0.1 – 0.1 – 0.1
Large cell/anaplastic 38 100 0.1 0.4 0.5 0.2 0.4 0.3 0.4
IIIc.2 Embryonal CNS tumour NOS 111 95.5 2.7 1.6 0.7 0.7 1.0 1.2 1.1
IIIc.3 Medulloepithelioma/neuroepithelioma 3 100 – < 0.05 0.1 – < 0.05 < 0.05 < 0.05
IIIc.4 Atypical teratoid/rhabdoid tumour 81 96.3 3.3 1.7 0.2 0.2 0.9 0.9 0.9
IIId.1 Oligodendroglioma 34 100 – 0.5 0.3 0.3 0.3 0.3 0.3
IIId.2 Mixed and unspecified gliomas 340 22.9 1.0 3.2 4.2 2.8 3.4 3.1 3.2
Unspecified 318 17.6 1.0 3.0 4.1 2.4 3.2 2.9 3.0
Mixed 19 100 – 0.1 0.1 0.4 0.2 0.2 0.2
Angiocentric glioma 3 100 – < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 < 0.05
IIId.3 Other neuroepithelial tumours 23 82.6 0.1 0.1 0.2 0.3 0.2 0.2 0.2
Gliomatosis cerebri 13 76.9 0.1 0.1 0.1 0.2 0.2 0.1 0.1
Papillary tumour of the pineal region 5 100 – – 0.1 0.1 < 0.05 0.1 < 0.05
Astroblastoma 5 80.0 – 0.1 < 0.05 0.1 < 0.05 0.1 < 0.05
IIIe.1 Pituitary adenoma 67 62.7 – 0.1 0.2 1.5 0.5 0.6 0.6
IIIe.2 Craniopharyngioma 191 82.7 0.1 1.2 2.2 2.2 1.8 1.7 1.7
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The ASR for total intracranial and intraspinal tumours
rose from 25.7 per million in 1971–75 to 41.3 per million
in 2006–10, an increase of 60% over 35 years. The corre-
sponding increases in age-specific rates (not shown in
Table 4) were: age 0, from 20.3 per million in 1971–75 to
42.9 per million in 2006–10, 108%; age 1–4, from 28.5 per
million in 1971–75 to 44.5 per million in 2006–10, 56%;
age 5–9, from 27.3 per million in 1971–75 to 40.5 per mil-
lion in 2006–10, 48%; age 10–14, from 22.5 per million in
1971–75 to 38.3 per million in 2006–10, 70%.
Incidence patterns over time varied markedly between
diagnostic categories. Astrocytoma was the most fre-
quent tumour type throughout, and its ASR rose from
8.7 per million in 1971–75 to 16.8 per million in 2006–
10, an increase of 93%. Between the same two periods,
the proportional increase was greater for pilocytic astro-
cytoma (202%, from 2.9 per million to 8.6 per million)
than for astrocytomas of other or unspecified subtype
(40%, from 5.8 per million to 8.2 per million), and higher
for optic nerve astrocytomas (286%, from 0.9 per million
to 3.4 per million) than for other sites (72%, from 7.8
per million to 13.4 per million). From 1991 onwards,
pilocytic astrocytoma was the most frequent single
histological type of tumour (Fig. 1).
Medulloblastoma, mixed and unspecified gliomas, and
ependymoma, all had very similar ASRs in 1971–75 and
2006–10, with fluctuating rates in the intervening periods.
Among the remaining, rarer categories, some showed little
sign of consistent change over time, such as oligodendro-
glioma and pineal parenchymal tumours. Several others
were registered extremely rarely in the earliest years.
Neuronal and mixed neuronal-glial tumours accounted
for no more than 1% of all tumours before 1991, but their
relative frequency rose to 2.6% in 1991–95 and 5.3% in
1996–2010, corresponding to increases in registration
rates initially for ganglioglioma and later for DNET and
DIA. Some tumours, notably ATRT and pituitary aden-
oma, were only recorded in substantial numbers in the
final decade.
When classified by ICD-O-3 behaviour code, incidence of
both non-malignant and malignant tumours increased be-
tween 1971 and 75 and 2006–10 (Table 4). The ASR for tu-
mours with non-malignant behaviour code increased by
137%, from 7.3 to 17.2 per million. The corresponding
change for malignant tumours was 30%, from 18.5 to 24.1
per million. For all tumours except ICCC-3 IIIb, astrocy-
toma, the increases in ASR were: non-malignant, 4.4–8.2 per
million, 86%, and malignant, 12.7–16.3 per million, 29%.
Contribution of second primary neoplasms
In 2001–10 there were 44 registrations for CNS tu-
mours as second or later primary neoplasms among
children (Table 5). Ependymomas accounted for 2
(5%), astrocytomas for 16 (36%), other gliomas for 5
(11%), embryonal tumours for 9 (20%), meningiomas
for 6 (14%), mixed glial-neuronal tumours for 3
Table 3 Intracranial and intraspinal tumours among children aged 0–14 years resident in Great Britain, 2001–2010. Numbers of
registrations (N), % microscopically verified (MV), rates per million children by age group, age standardised rates (world standard
population) (ASR) by sex (Continued)
ASR
ICCC-3 N %MV 0 1–4 5–9 10–14 M F Total
IIIe.3 Pineal parenchymal tumours 46 97.8 0.4 0.4 0.4 0.4 0.4 0.4 0.4
Pineocytoma 4 100 – < 0.05 0.1 < 0.05 < 0.05 < 0.05 < 0.05
Pineoblastoma incl. PTID 42 97.6 0.4 0.4 0.4 0.4 0.4 0.4 0.4
IIIe.4 Mixed glial-neuronal tumours 223 91.5 3.1 1.6 1.9 2.6 2.3 1.8 2.1
Desmoplastic infantile astrocytoma 21 100 2.1 0.1 0.1 < 0.05 0.3 0.1 0.2
Dysembryoplastic neuroepithelial tumour 91 86.8 0.1 0.7 0.9 1.1 1.0 0.7 0.8
Ganglioglioma 96 93.8 0.6 0.7 0.8 1.3 0.9 0.9 0.9
Central neurocytoma 6 83.3 0.1 0.1 < 0.05 0.1 0.1 – 0.1
Papillary glioneuronal tumour 3 100 – – 0.1 < 0.05 < 0.05 < 0.05 < 0.05
Gangliocytoma 6 100 0.1 0.1 0.1 < 0.05 < 0.05 0.1 0.1
IIIe.5 Meningioma 50 88.0 0.1 0.3 0.3 0.8 0.4 0.5 0.4
IIIf Unspecified tumours 196 19.9 4.5 1.6 1.5 1.9 2.0 1.8 1.9
Xa Germ cell tumours 170 77.6 2.0 0.7 1.0 2.9 1.9 1.1 1.5
Germinoma 119 76.5 0.1 < 0.05 0.8 2.4 1.3 0.7 1.0
Other 51 80.4 1.8 0.7 0.1 0.4 0.6 0.4 0.5
Total 4166 78.8 40.7 44.4 38.6 37.0 42.6 37.5 40.1
Source: National Registry of Childhood Tumours
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(7%), unspecified tumours for 2 (5%) and germ-cell
tumours for 1 (2%). There were no choroid plexus
tumours, pituitary tumours, craniopharyngiomas or
pineal parenchymal tumours. Thirty-four tumours
(77%) were in children aged 10–14 years. Second pri-
maries represented 1% of all childhood CNS tu-
mours, but 11% of oligodendrogliomas and
meningiomas. The proportion of childhood CNS tu-
mours that were second primaries rose from zero in
the first year of life to 0.2% at age 1–4, 0.5% at age
5–9 and 2.5% at age 10–14.
Discussion
The data presented here give up to date estimates of the
incidence of intracranial and intraspinal tumours among
children in Great Britain. Total annual incidence during
2001–10 was 40.1 per million, equivalent to a risk of 1
in 1678 that a child will be diagnosed with such a
tumour before their 15th birthday. About 40% of inci-
dence was accounted for by astrocytomas. The most fre-
quent single histological type of tumour was pilocytic
astrocytoma, which accounted for one half of all astrocy-
tomas and 21% of all tumours. If it is assumed that
Table 4 Intracranial and intraspinal tumours among children aged 0–14 years resident in Great Britain, 1971–2010. Numbers of
registrations (N) and age-standardised rates (world standard population) (ASR) in successive quinquennia of diagnosis, by ICCC-3
category and ICD-O-3 behaviour code
ICCC-3 1971–1975 1976–1980 1981–1985 1986–1990 1991–1995 1996–2000 2001–2005 2006–2010
N ASR N ASR N ASR N ASR N ASR N ASR N ASR N ASR
IIIa.1 Ependymoma 181 2.9 164 3.0 131 2.6 121 2.4 127 2.4 134 2.6 139 2.8 152 3.0
IIIa.2 Choroid plexus tumours 13 0.2 24 0.5 31 0.7 28 0.6 43 0.9 48 1.0 54 1.2 57 1.2
IIIb Astrocytoma 563 8.7 611 10.3 518 9.7 606 11.8 780 14.4 786 14.5 842 16.1 865 16.8
Pilocytic, optic nerve 12 0.2 16 0.3 10 0.2 15 0.3 25 0.5 22 0.4 31 0.7 29 0.6
Pilocytic, other sites 173 2.7 222 3.7 162 3.0 181 3.5 256 4.7 360 6.6 382 7.2 418 8.0
Other non-malignant behaviour 2 <
0.05
5 0.1 3 <
0.05
5 0.1 13 0.2 23 0.4 21 0.4 21 0.4
Malignant behaviour, optic nerve 43 0.7 49 0.9 46 0.9 52 1.1 71 1.4 102 2.0 113 2.3 139 2.8
Malignant behaviour, other sites 333 5.1 319 5.3 297 5.5 353 6.8 415 7.6 279 5.1 295 5.5 258 5.0
IIIc.1 Medulloblastoma 316 5.0 306 5.3 277 5.4 237 4.6 256 4.8 254 4.7 272 5.3 252 4.9
IIIc.2 Embryonal CNS tumour NOS 2 <
0.05
9 0.2 40 0.8 70 1.4 86 1.7 75 1.5 50 1.0 59 1.2
IIIc.3 Medulloepithelioma/
neuroepithelioma
1 <
0.05
2 <
0.05
0 – 2 <
0.05
5 0.1 2 <
0.05
2 <
0.05
1 <
0.05
IIIc.4 Atypical teratoid/rhabdoid
tumour
0 – 0 – 0 – 2 <
0.05
2 <
0.05
22 0.5 32 0.7 49 1.0
IIId.1 Oligodendroglioma 34 0.5 21 0.3 33 0.6 24 0.5 19 0.3 13 0.2 14 0.3 20 0.4
IIId.2 Mixed and unspecified gliomas 225 3.4 227 3.8 179 3.4 185 3.5 162 3.0 174 3.2 169 3.2 171 3.3
IIId.3 Other neuroepithelial tumours 3 0.1 0 – 2 <
0.05
5 0.1 4 0.1 1 <
0.05
6 0.1 17 0.3
IIIe.1 Pituitary adenoma 5 0.1 10 0.1 6 0.1 6 0.1 10 0.2 10 0.2 30 0.5 37 0.6
IIIe.2 Craniopharyngioma 70 1.1 91 1.5 65 1.2 77 1.4 105 1.9 98 1.7 91 1.6 100 1.9
IIIe.3 Pineal parenchymal tumours 25 0.4 31 0.6 22 0.3 17 0.3 16 0.3 23 0.4 24 0.5 22 0.4
IIIe.4 Mixed glial-neuronal tumours 5 0.1 6 0.1 10 0.2 15 0.3 48 0.9 100 1.8 104 1.9 119 2.2
IIIe.5 Meningioma 26 0.4 21 0.3 21 0.3 15 0.3 31 0.5 17 0.3 22 0.4 28 0.5
IIIf Unspecified tumours 153 2.3 61 1.1 83 1.6 86 1.7 104 1.9 67 1.3 97 1.9 99 1.9
Xa Germ cell tumours 33 0.5 50 0.8 67 1.2 56 1.1 82 1.5 85 1.5 83 1.5 87 1.6
ICD-O-3 behaviour
0,
1
Non-malignant 475 7.3 481 8.2 407 7.5 429 8.3 623 11.5 746 13.6 823 15.5 903 17.2
3 Malignant 1180 18.5 1153 19.8 1078 20.5 1123 21.8 1257 23.4 1163 21.8 1208 23.5 1232 24.1
Total 1655 25.7 1634 28.0 1485 28.1 1552 30.1 1880 34.9 1909 35.4 2031 38.9 2135 41.3
Source: National Registry of Childhood Tumours
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almost all unspecified optic nerve gliomas and astrocyto-
mas in children are actually pilocytic astrocytomas [22,
23], these proportions increase to 65 and 27% respect-
ively. Embryonal tumours, predominantly medulloblas-
toma, accounted for 17% of all registrations, and
ependymomas and other gliomas together for 17%. The
remaining 25% consisted of a wide range of other, rarer
entities together with a small contribution from tumours
of unspecified type.
In addition to providing current estimates of incidence
for the most frequent and long-established types of
childhood CNS tumour, the data also include reasonable
Fig. 1 Age-standardised rates of childhood astrocytoma in Great Britain by five-year calendar period of diagnosis, 1971–2010
Table 5 Intracranial and intraspinal tumours as second or later primary neoplasms among children aged 0–14 years resident in
Great Britain, 2001–2010. Numbers of cases by age group, with total numbers of cases as first or only primary neoplasm for
comparison
Second neoplasms by age at diagnosis (years) First neoplasms
ICCC-3 0 1–4 5–9 10–14 Total Total
IIIa Ependymoma & choroid plexus tumours 0 0 0 2 2 402
IIIa.1 Ependymoma 0 0 0 2 2 291
IIIb Astrocytoma 0 2 1 13 16 1707
IIIc Embryonal tumours 0 0 2 7 9 717
IIIc.1 Medulloblastoma 0 0 2 0 2 522
IIIc.2 Embryonal CNS tumour NOS 0 0 0 6 6 111
IIIc.4 ATRT 0 0 0 1 1 81
IIId Other gliomas 0 0 1 4 5 397
IIId.1 Oligodendroglioma 0 0 0 4 4 34
IIId.2 Mixed and unspecified gliomas 0 0 1 0 1 340
IIIe Other specified tumours 0 1 1 7 9 577
IIIe.4 Mixed glial-neuronal tumours 0 0 1 2 3 223
IIIe.5 Meningioma 0 1 0 5 6 50
IIIf Unspecified tumours 0 0 1 1 2 196
Xa Germ cell tumours 0 0 1 0 1 170
Total 0 3 7 34 44 4166
Source: National Registry of Childhood Tumours
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numbers of cases of several tumours that entered ICD-O
at the third edition [16]. The most numerous of these is
DNET, a low-grade glioneuronal tumour whose inci-
dence increases steadily with age throughout childhood.
DNET has similar incidence to ganglioglioma, account-
ing for about 40% of mixed glial-neuronal tumours and
2% of all CNS tumours.
ATRT is the third most frequent embryonal CNS tumour,
after medulloblastoma and embryonal CNS tumour NOS.
It predominantly occurs in very early childhood, and in the
first year of life its incidence is similar to that of medullo-
blastoma and embryonal CNS tumour NOS. In the past,
most cases would have been diagnosed as medulloblastoma
or PNET, which ATRT can resemble morphologically [24].
In a UK series of 42 centrally reviewed cases of embryonal
CNS tumour NOS, six (14%) were reclassified as ATRT be-
cause of INI1-immunonegativity and presence of rhabdoid
cells [25].
Pilomyxoid astrocytoma was formerly regarded as a
relatively aggressive variant of pilocytic astrocytoma. In
the present data it accounted for 2.2% of all astrocyto-
mas and 4.2% of the total of pilocytic and pilomyxoid as-
trocytomas. Incidence was highest in the first year of
life, when it accounted for 14% of all astrocytomas and
38% of pilocytic and pilomyxoid tumours. These relative
frequencies are probably underestimates. In a diagnostic
review of all tumours labelled pilocytic or pilomyxoid as-
trocytoma over a 14-year period at one neurosurgical
centre, 9/91 (10%) of all cases and 6/40 (15%) in children
aged under 15 had a final diagnosis of pilomyxoid astro-
cytoma [26].
DIA, sometimes formerly known as desmoplastic in-
fantile ganglioglioma, is also classified as a glioneuronal
tumour. As its name suggests, it is overwhelmingly a
tumour of very early life. About 5% of all CNS tumours
in infants were DIA in the present series. All other
tumour types that were new to ICD-O with the third
edition [16] or its first revision [19] were extremely rare,
with fewer than 2 registrations per year.
The patterns of incidence described here for Britain
are broadly similar to those observed in recent national
registration data from France [17], the United States [18]
and Australia [27] (Table 6). Total age-standardised inci-
dence ranged from 37.5 per million in Australia to 47
per million in the United States. Astrocytoma was every-
where the most common subgroup, accounting for 36–
43% of total incidence, and astrocytoma plus other gli-
omas accounted for 48–54%. Embryonal tumours
accounted for 18–20% of total incidence in all four
countries.
Table 6 Incidence of intracranial and intraspinal tumours among children aged 0–14 years in Great Britain (NRCT), France [17], the
United States [18] and Australia [27]. Age-standardised rates (world standard population) per million; rates for United States
calculated using case numbers and denominators from Table 8 and Appendix B respectively of reference 18
Great Britain France United States Australia
ICCC-3 2001–2010 2000–2008 2006–2010 1997–2006
IIIa Ependymoma & choroid plexus tumours 4.1 3.8 4.3 3.4
IIIa.1 Ependymoma 2.9 2.6 3.0 –
IIIa.2 Choroid plexus tumours 1.2 1.2 1.3 –
IIIb Astrocytoma 16.4 13.7 17.3 16.2
IIIc Embryonal tumours 7.1 7.7 8.4 7.2
IIIc.1 Medulloblastoma 5.1 5.4 – –
IIIc.2 Embryonal CNS tumour NOS 1.1 1.1 – –
IIIc.4 ATRT 0.9 1.1 – –
IIId Other gliomas 3.7 4.9 6.1 4.2
IIId.1 Oligodendroglioma 0.3 1.6 0.5 –
IIIe Other specified tumours 5.3 6.0 8.2 3.9
IIIe.1 Pituitary adenoma 0.5 0.2 1.7 –
IIIe.2 Craniopharyngioma 1.7 1.8 2.0 –
IIIe.3 Pineal parenchymal tumours 0.5 0.3 0.4 –
IIIe.4 Mixed glial-neuronal tumours 2.1 3.2 3.2 –
IIIe.5 Meningioma 0.4 0.6 0.8 –
IIIf Unspecified tumours 1.9 0.6 1.7 0.9
Xa Germ cell tumours 1.5 2.1 1.8 1.8
Total 40.1 38.8 47.0 37.5
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The excess in the United States was largely attribut-
able to ICCC-3 subgroups IIId (‘Other gliomas’) and IIIe
(‘Other specified tumours’) (Table 6 and Fig. 2). Within
the broad category of gliomas, recorded incidence of as-
trocytoma was 10% higher in the United States at age 0–
4 but only 2–4% higher within the 5–14 year age range.
Incidence of other gliomas, mainly unspecified, in the
United States was about 1.6 times that in Britain; the %
MV was not stated [18]. The other categories that had
markedly higher rates in the United States were: neur-
onal/glial tumours, about 1.5 times as frequent as in
Britain; meningioma, twice as frequent; and pituitary tu-
mours, about 3.5 times as frequent [18]. It is impossible
to know how much of these differences is due to higher
levels of ascertainment and how much to earlier diagno-
sis of predominantly low-grade tumours that can have a
protracted natural history. The excess of glio-neuronal
tumours was slightly higher at age 5–14 (1.6 times) than
at age 0–4 (1.4 times), suggesting that incidence of
DNET, in particular, is substantially higher in the United
States. The British data excluded second primary tu-
mours, but their inclusion would only have increased
A B
C D
E F
G
Fig. 2 Age-specific rates of selected types of CNS tumours in Great Britain 2001–2010 (present study) and the United States 2006–2010 [18]
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the total number of registrations for childhood meningi-
omas by 12%, a very small part of the difference between
the two countries. Proportionally, the largest difference
in incidence was for pituitary adenoma, with ASR of 0.5
per million in Britain and 1.7 in the United States. Regis-
tration of this tumour was certainly incomplete in Brit-
ain in the past. Published case series from two major
treatment centres in London contain sufficient information
for a case-by-case comparison with registry data. One series
[28] included 11 children diagnosed in 1982–96, of whom a
maximum of 4 (36%) were registered. The other [29, 30] in-
cluded 26 children diagnosed in 1983–2008 of whom no
more than 4 (15%) were registered. Thus the maximum esti-
mate of the proportion registered from the combined series
was only 8/37 (22%). The difference between the two coun-
tries in incidence of craniopharyngioma was relatively small
but age at diagnosis was younger in the United States (Fig.
2), which may tend to support earlier diagnosis as an explan-
ation for some of the other differences.
In France, incidence of oligodendroglioma was consid-
erably higher than elsewhere and incidence of astrocy-
toma correspondingly lower, perhaps because French
pathologists are more influenced by the St Anne classifi-
cation in which some diffuse or anaplastic astrocytomas
are considered as oligodendrogliomas [31]. Total inci-
dence in Australia was somewhat lower than in Britain,
with the deficit accounted for by ICCC-3 subgroups IIIa
ependymoma and choroid plexus tumours, IIIe other
specified tumours and IIIf unspecified tumours, consist-
ent with under-recording of non-malignant tumours, al-
though it was stated that these were registered in
Australia [27].
In the four Nordic countries of mainland Europe during
1985–2006, when incidence of childhood CNS tumours
was stable over time, the ASR for ICCC-3 group III (i.e.
excluding germ-cell tumours) was 42.0 per million [32],
compared with 38.6 per million in Britain during 2001–
10. The excess in the Nordic countries was less pro-
nounced at age 10–14 than in the first decade of life, and
was concentrated in astrocytoma (ASR 17.9 per million)
and unspecified tumours (3.2 per million). In Sweden dur-
ing 1984–2005, incidence rates were similar to those re-
ported for the combined Nordic countries; optic nerve/
chiasm gliomas had an ASR of 3.8 per million and
accounted for 17% of astrocytomas, and 67% were diag-
nosed before age 5 years [33]. In Britain during 2001–10,
optic nerve gliomas had an ASR of 3.2 per million and
accounted for 18% of astrocytomas; 56% were diagnosed
at age under 5 years. The lower ASR and lower proportion
diagnosed at young ages indicate that diagnosis of optic
nerve gliomas is delayed in Britain compared to Sweden.
The German Childhood Cancer Registry (GCCR) regis-
tered 4270 tumours in ICCC-3 Group III and subgroup
Xa during 1998–2007 [34]. Embryonal tumours accounted
for a higher proportion of registrations (21%) than in Brit-
ain (17%). Astrocytomas also had a higher relative fre-
quency than in Britain (45% vs 41%), offset by lower
relative frequencies of other gliomas (7.5% vs 9.5%) and
unspecified tumours (1.4% vs 4.7%). More detailed data
on CNS tumours in the GCCR have been published for
the periods 1990–9 and 1980–99 [35]. Compared with
Britain, Germany had a lower ratio of medulloblastoma to
embryonal CNS tumour NOS which may be related to the
exceptionally close relationship between the GCCR and
national clinical trials. The GCCR also had a lower ratio
of pineoblastoma to non-malignant pineal parenchymal
tumours, for which it is difficult to suggest a plausible
explanation.
Many cancer registries, while generally restricting their
coverage to malignant neoplasms, also systematically col-
lect data on non-malignant tumours of certain sites be-
cause of their pre-malignant status, or because they are
potentially lethal and the distinction from malignant tu-
mours can be difficult and opinion as to malignancy has
changed over time. The former category is exemplified by
tumours of the bladder and cervix. CNS and other intra-
cranial tumours are the most important example of the
latter. Some important childhood tumours of these sites,
including craniopharyngioma, have always been classed as
non-malignant, and will thus have been consistently ex-
cluded from presentations of data that are limited to ma-
lignant tumours. Many population-based cancer registries
in Europe, and all specialist childhood cancer registries,
have traditionally registered all CNS tumours regardless of
behaviour. By contrast, most state cancer registries in the
United States, notably those affiliated to the Surveillance,
Epidemiology and End Results (SEER) Program of the Na-
tional Cancer Institute, did not systematically record or
publish data on non-malignant CNS tumours [18]. How-
ever, this gap was filled following the passing of the Benign
Brain Tumor Cancer Registries Amendment Act in 2002,
with all population-based cancer registries in the United
States ascertaining non-malignant CNS tumours diag-
nosed from 2004 onwards [18]. The Central Brain Tumor
Registry of the United States (CBTRUS) has aggregated data
from an increasing number of state cancer registries to pro-
vide high-quality, population-based statistical data on primary
malignant and non-malignant brain and CNS tumours; its re-
port for 2006–10 assembled data from 50 state cancer regis-
tries participating in the SEER Program or the National
Program of Cancer Registries, representing over 98% of the
national population [18]. Many major cancer registries in
other world regions that formerly collected only malignant tu-
mours now also register non-malignant CNS tumours, for ex-
ample the Korea Central Cancer Registry as from 2005 [36].
While non-registration of tumours that have always
been regarded as non-malignant leads to underestimates
of both incidence and survival for total CNS tumours, the
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effect is at least reasonably constant over time. Compar-
ability and continuity of data over time are disrupted if the
definition of malignancy changes. The data presented here
illustrate the severity of the problem when pilocytic astro-
cytoma, the most frequent of all childhood CNS tumours,
undergoes a change of behaviour code. It would not be suf-
ficient to report just the tumours that were coded as malig-
nant in ICD-O-3 because unspecified astrocytoma has
always been coded as malignant and it is clear that higher
proportions of pilocytic astrocytomas were recorded as un-
specified astrocytoma in earlier years. The effect of inclu-
sion/exclusion of pilocytic astrocytoma from survival
estimates was illustrated in the EUROCARE-4 study, where
5-year survival for children in Europe with astrocytoma diag-
nosed in 2000–02 was 63% when tumours specified as pilo-
cytic were excluded and 78% when they were included [37].
In EUROCARE-5, age-standardised 5-year survival for chil-
dren with malignant astrocytoma defined according to
ICD-O-3, so excluding pilocytic astrocytoma, was 64.3% in
1999–2001, 54.5% in 2002–04 and 59.1% in 2005–07 [38].
The decrease in survival after 2002 was probably an artefact
of larger numbers of pilocytic astrocytomas being coded as
such, and thus excluded, and correspondingly fewer being
coded as astrocytoma NOS. Also in EUROCARE-5, 5-year
survival for all children with astrocytoma diagnosed in
2000–07 was 80% [39]. For the more numerous specific sub-
types, survival ranged from 95 to 100% for pilocytic astrocy-
toma, optic nerve glioma and SEGA (all WHO Grade I) and
75–85% for fibrillary astrocytoma and pleomorphic
xanthoastrocytoma (both Grade II) to 21% for anaplastic as-
trocytoma (Grade III) and 14% for glioblastoma (Grade IV).
For astrocytoma NOS, which accounted for 16% of all astro-
cytomas and 35% of those with malignant behaviour code,
5-year survival was 74% [39]. This group would have con-
sisted of unknown proportions of diffuse astrocytoma (Grade
II) and of tumours of unspecified subtype whose grade was
not reported.
The present study concerns childhood tumours but it is
equally important that non-malignant tumours diagnosed
at older ages are registered. In England during 1995–2003,
when pilocytic astrocytoma was still coded as malignant,
17% of CNS tumours diagnosed at age 0–14 were of un-
certain, borderline or benign behaviour, compared with
41% at age 15–24 and 42% at age 25–84 [22]. Meningi-
omas and pituitary tumours, the great majority of which
are non-malignant, accounted for 17 and 9% respectively
of CNS tumours at age 25–84 during that period [22]. In
the United States in 2006–10, non-malignant tumours
accounted for about 30% of total age-adjusted CNS
tumour incidence in children aged 0–14 years and two
thirds of age-adjusted incidence in adults above 20 years
of age [18].
In common with many other countries, the British
registration data for childhood CNS tumours showed an
increase in recorded incidence over time for most of the
study period. While there have been major shifts in as-
signment of specific tumour types to malignant or
non-malignant categories over the years, no entities have
switched from neoplastic to non-neoplastic or vice versa
in the ICD. Therefore, changes in recorded incidence of
CNS tumours overall or of any subtype must be due to
changes in underlying risk, changes in the proportion
actually diagnosed before the 15th birthday, or changes
in completeness of ascertainment of diagnosed tumours
by the registration system. A study of time trends in
registration rates for all types of childhood cancer in
Britain between 1966 and 2005 found that changes in in-
cidence of CNS tumours considered as a single group
correlated well with contemporaneous changes in diag-
nostic and registration practice [40]. It did not, however,
seek to explain changes over time in rates for specific
tumour types or in the ratio of rates for one type to an-
other. Some tumour types were registered hardly ever, if
at all, in the earliest years, and only in appreciable num-
bers later in the study period. This most obviously ap-
plies to embryonal CNS tumour NOS (from the 1980s
onwards) and ATRT (from the mid-1990s). Registrations
for mixed glial-neuronal tumours were also extremely
rare in the 1970s but the numbers increased steadily
through the following decades as ganglioglioma was
more frequently registered in the 1980s, followed by
DIA and DNET from the mid-1990s, the latter probably
resulting from increasing surgery for epilepsy. The in-
crease in germ-cell tumours from the 1980s was partly
offset by a decline in pineal parenchymal tumours, per-
haps because some cases of germinoma would have been
registered as pinealoma in the early years. Pituitary ad-
enoma is known to have been under-registered, as dis-
cussed above. The relative contribution of earlier
diagnosis and improved ascertainment to the steep in-
crease in recorded incidence is unknown. Even in the
most recent years, incidence was still markedly lower
than in the United States. The increase in choroid plexus
tumours is perhaps hardest to account for. Choroid
plexus papilloma and carcinoma were both well-defined
and described before the 1970s, and there was no clear
trend over time in the ratio of papilloma to carcinoma.
Within the broad group of astrocytomas, optic nerve
tumours increased in incidence more steeply than those
of other sites (Table 4). Moreover, the proportions of
optic nerve gliomas that were diagnosed before the age
of 5 years were 40% in 1971–80, 62% in 1981–90, 53% in
1991–2000 and 56% in 2001–10, consistent with a ten-
dency to earlier diagnosis since about 1980. Neverthe-
less, as discussed above, the data presented here are
compatible with diagnosis of lower grade CNS tumours
occurring later in Britain than in some other countries.
Earlier diagnosis is important because, even if overall
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survival is unaffected, disease progression is likely to be
less severe [41]. The ‘HeadSmart: Be Brain Tumour
Aware’ campaign improved awareness of childhood brain
tumours in the UK and was associated with a 7-week re-
duction in median total diagnostic interval [42]. Other
factors that could adversely affect time to diagnosis in-
clude availability of magnetic resonance imaging scan-
ners, for which UK provision per million population has
been lower than in many other OECD countries [43].
This study has several considerable strengths. The re-
sults are derived from a very large population-based data
set. Non-malignant tumours were eligible and routinely
included throughout the study period. Access to diagnos-
tic reports for the great majority of cases allowed a high
degree of specificity in coding, including the possibility of
manual recoding of tumours when updating to successive
revisions of the coding system. Even so, in some cases it
was impossible to obtain evidence regarding whether a
tumour was microscopically verified, so the MV percent-
ages in Table 3 should be regarded as minimum estimates.
The most important limitation is that central diagnostic
review is impracticable for such a large national series,
hence accuracy of diagnosis is an obvious concern. During
2001–10, childhood brain tumours were diagnosed patho-
logically in 21 hospitals throughout Britain, and the num-
ber in earlier years was much greater (data not shown).
The potential effects are illustrated by the results of path-
ology review in a Children’s Cancer Group study of
high-grade gliomas in North America, in which only 69%
of tumours with an institutional diagnosis of high-grade
glioma were confirmed as high-grade glioma by the review
panel, and levels of agreement for specific tumour types
such as anaplastic astrocytoma and glioblastoma multi-
forme were even lower [44]. In a UK study of low-grade
glioma, however, only 33/713 (5%) of those with central
histology review were excluded because of ineligible or in-
conclusive histology or no evidence of tumour [45]. In
international trials where UK centres contributed the ma-
jority of patients, 12% of tumours with a local diagnosis of
supratentorial embryonal CNS tumour NOS were found
not to be embryonal CNS tumour NOS on review [46]
and 13% of children under 3 years of age with a tumour
other than ependymoma had their diagnosis changed on
review [47]. The proportions of tumours such as cranio-
pharyngioma for which histological subtype was recorded
was disappointingly low. In some cases this was because a
copy of the original pathology report was not obtained,
but there were certainly some cases for which the report
did not specify a subtype (data not shown).
While this study documents the evolving patterns of
recorded incidence of childhood CNS tumours in suc-
cessive quinquennia over a 40-year period, it is not a for-
mal analysis of time trends and confidence intervals for
rates are not provided.
In the absence of central review, the data presented
here give the most accurate indication of childhood CNS
tumour incidence based on histological criteria. Many
tumours, however, would likely be reclassified on review
using the genotypic criteria of WHO 2016, e.g. some
cases of brainstem glioma or diffuse intrinsic pontine
glioma could be redefined as diffuse midline glioma H3
K27M-mutant [13]. Universal application of WHO 2016
criteria would inevitably modify the demographics of in-
cidence by tumour type, and the use of these less sub-
jective molecular criteria may also reduce variation in
tumour diagnoses between institutions and geographic
areas. However, definitive population-level description of
childhood CNS tumour incidence according to WHO
2016 will only be possible when several years’ registra-
tion data according to the new criteria become available.
Conclusions
Total incidence of childhood CNS tumours in Britain in
the first decade of the new millennium was fairly similar
to that in other large western countries. Deficits of some,
predominantly low-grade, tumours or differences in their
age distribution compared with the United States and
the Nordic countries are compatible with delayed diag-
nosis in Britain. Complete registration of all types of
CNS tumour, regardless of behaviour, is essential for
assessing burden of disease and changes over time in in-
cidence and survival. This is particularly important for
pilocytic astrocytoma, the most common of all child-
hood CNS tumours, because of the recent change in its
behaviour code from malignant to non-malignant and
changes over time in the proportion of astrocytomas for
which subtype has been specified.
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